{
    "body": "Describe mechanism of action of PLX3397 drug.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24718867", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24247719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25110953", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26222558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25042473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26156998", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24583793"
    ], 
    "ideal_answer": [
        "PLX3397 works by inhibiting colony-stimulating-factor-1 receptor (CSF1R)."
    ], 
    "type": "summary", 
    "id": "56c07ef5ef6e394741000023", 
    "snippets": [
        {
            "offsetInBeginSection": 658, 
            "offsetInEndSection": 762, 
            "text": "Following the 25 d lesion, we administered PLX3397, a CSF1R inhibitor, for 30 d to eliminate microglia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26156998", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 235, 
            "offsetInEndSection": 429, 
            "text": ".METHODS: Using x-ray co-crystallography to guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps the kinase in the autoinhibited conformation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26222558", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 429, 
            "offsetInEndSection": 636, 
            "text": "Treatment with PLX3397, a small molecule inhibitor of the CSF1 receptor CSF1R and related kinases, decreases microglial numbers by promoting microglial apoptosis in both CSF1 overexpressing and control mice.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042473", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 156, 
            "text": "Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24718867", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 257, 
            "offsetInEndSection": 504, 
            "text": "We hypothesized that PLX3397, which inhibits KIT and colony-stimulating-factor-1 receptor (CSF1R), would be more efficacious than imatinib in GIST by also depleting tumor-associated macrophages, which are generally thought to support tumor growth.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24583793", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 97, 
            "offsetInEndSection": 515, 
            "text": "The cytokine CSF-1 (or M-CSF) is an important factor of TAM recruitment and differentiation and several pharmacological agents targeting the CSF-1 receptor (CSF-1R) have been developed to regulate TAM in solid cancers. We show that the kinase inhibitor PLX3397 strongly dampened the systemic and local accumulation of macrophages driven by B16F10 melanomas, without affecting Gr-1(+) myeloid derived suppressor cells. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110953", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 184, 
            "offsetInEndSection": 297, 
            "text": "The CSF-1 receptor (CSF-1R) is a tyrosine kinase that is targetable by small molecule inhibitors such as PLX3397.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 981, 
            "offsetInEndSection": 1145, 
            "text": "In conclusion, CSF-1R blockade with PLX3397 improved the efficacy of ACT immunotherapy by inhibiting the intratumoral accumulation of immunosuppressive macrophages.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 296, 
            "offsetInEndSection": 409, 
            "text": "The CSF-1 receptor (CSF-1R) is a tyrosine kinase that is targetable by small molecule inhibitors such as PLX3397.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1138, 
            "offsetInEndSection": 1302, 
            "text": "In conclusion, CSF-1R blockade with PLX3397 improved the efficacy of ACT immunotherapy by inhibiting the intratumoral accumulation of immunosuppressive macrophages.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 184, 
            "offsetInEndSection": 298, 
            "text": "The CSF-1 receptor (CSF-1R) is a tyrosine kinase that is targetable by small molecule inhibitors such as PLX3397. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247719", 
            "endSection": "abstract"
        }
    ]
}